We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You canĀ read more about our cookies before you choose.
Urgent clinical commissioning policy statement: Vestronidase alfa for Mucopolysaccharidosis Type VII (MPS, Sly syndrome) (infantile)
Vestronidase alfa is recommended to be available as a routine commissioning as a treatment option for infants with MPS VII within the criteria set out in this document.